Navigation Links
Elusys' Anthrax Anti-Toxin, Anthim(TM), Enters Second Phase I Clinical Study
Date:4/20/2009

tection when given within 12 hours of an anthrax exposure. These results have been consistent across studies whether Anthim was used with or without antibiotics. Our first Phase I human safety study demonstrated that Anthim is safe and well-tolerated as a monotherapy and as a combined therapy with the antibiotic ciprofloxacin. This second study will continue to expand our safety database and provide additional pharmacokinetic data."

Dr. Posillico added, "Death from the effects of anthrax toxin can occur in a few days if patients are not treated quickly. We are very excited about Anthim because the results of all of our studies show that treatment with Anthim has the potential to provide significant therapeutic benefit for people infected with anthrax in a bioterrorism emergency." Currently antibiotics represent the only therapeutic option for anthrax infection. Antibiotics target the bacteria, but can still fail to prevent death from the damaging effects of anthrax toxins. In addition, antibiotic resistant strains of anthrax could be used in a bioterror attack, making the medical need for anti-toxin therapy even more acute.

Anthim Background

Anthim is a high-affinity, humanized and deimmunized monoclonal antibody that targets the protective antigen of B. anthracis and neutralizes the lethal effects of anthrax toxins. It is being developed for prevention and treatment of inhalation anthrax. Anthim has been granted Fast-Track status and Orphan Drug Designation by the FDA. The National Institutes of Health and the Department of Defense have awarded Elusys a total of $34 million for the development of Anthim, of which $12 million was awarded in September 2007 under contract #HHSN272200700035 from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, and the Biomedical Advanced Research and Development Authority (BARDA), part of the Department of Hea
'/>"/>

SOURCE Elusys Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Niaid / Barda Awards Elusys a $12 Million Contract to Further Develop Anthim, the Companys Anthrax Therapeutic
2. Human Genome Sciences Begins Delivery of First-in-Class Anthrax Treatment to U.S. Strategic National Stockpile
3. New Approach to Treating Anthrax Significantly Improves Survival Rates in Pivotal Efficacy Studies
4. Advanced Life Sciences Collaborates with U.S. Government to Study Cethromycin as Treatment for Anthrax and Other High-Priority Biodefense Agents
5. Delcath Continues Expansion of Clinical Trial Centers Offering PHP(TM)
6. Another LNA-based RNA Inhibitor Enters Clinical Trials
7. Sanofi Pasteur Dengue Vaccine Enters Pediatric Efficacy Clinical Study
8. ESBATechs Antibody Fragment Enters Phase Ib/IIa in Ophthalmology
9. ESBATechs Antibody Fragment Enters Phase I/IIa Clinical Development in Osteoarthritis with the Potential for Disease-Modifying Activity
10. ELAD(R) Liver Support System Study Initiated at Multiple U.S. Centers
11. PreMD Inc. Enters Clinical Study with Cosmetics Conglomerate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... , July 25, 2014 /PRNewswire-iReach/ -- Dr. Michael ... clinic, GPM Pediatrics, reacts to a recent study, which shows ... Photo - http://photos.prnewswire.com/prnh/20140723/129709 According ... to severe stress are more likely than others to grow ... before pregnancy." There were two specific types of ...
(Date:7/24/2014)... Deutschland, und MARSEILLE , ... , Weltweite Exklusivlizenz der ... QIAGEN die Entwicklung von Tests auf SF3B1-Mutationen, ... Neuer Test weist Mutationen des ... (myelodysplastischen Syndromen) einen günstigen Krankheitsverlauf vermuten lassen  ...
(Date:7/24/2014)...  IRIDEX Corporation (NASDAQ: IRIX ) today ... financial results after the market closes on Thursday, ... the Company will host a conference call with the ... Thursday, July 31, 2014 to discuss ... Interested parties may access the live conference ...
Breaking Medicine Technology:Dr. Michael Gabriel of GPM Pediatrics, a Noted Staten Island Pediatrics Clinic, Comments on Study, Which Names Grief as a Cause of Obesity in Children 2QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 2QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 3QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 4QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 5
... Neurosciences Inc. ("Knopp"),announced that the U.S. Food ... has granted orphan drug designation to KNS-760704 ... (Logo: http://www.newscom.com/cgi-bin/prnh/20070924/KNOPPLOGO ) ... to evaluate the safety,tolerability and pharmacokinetics of ...
... to be Treated for This ... Aggressive Cancer at Home, PHILADELPHIA, ... Food and Drug Administration,(FDA) for oral HYCAMTIN(R) (topotecan) capsules for the ... are indicated for patients who had a,complete or partial response to ...
Cached Medicine Technology:Knopp Neurosciences Receives Orphan Designation for KNS-760704 for Treatment of ALS 2GSK Receives Approval for HYCAMTIN(R) (topotecan) Capsules for the Treatment of Relapsed Small Cell Lung Cancer 2GSK Receives Approval for HYCAMTIN(R) (topotecan) Capsules for the Treatment of Relapsed Small Cell Lung Cancer 3GSK Receives Approval for HYCAMTIN(R) (topotecan) Capsules for the Treatment of Relapsed Small Cell Lung Cancer 4
(Date:7/27/2014)... July 27, 2014 The inaugural ... demonstrate their passion for protecting our environment and getting ... the Southwest, will go on hiking or camping outings, ... show their support for permanently protecting our land, water ... the Latino community’s perspective on the environment like the ...
(Date:7/27/2014)... Vancouver, BC (PRWEB) July 27, 2014 ... have recently announced their demonstration depicting the hamstring release ... Backs in Action Wellness Center in Vancouver and have ... The hamstring release procedure was carried out by the ... The purpose of the exercise is to release tight ...
(Date:7/27/2014)... (PRWEB) July 27, 2014 This ... Global and Chinese Dutasteride (CAS 164656-23-9) industry. The ... (CAS 164656-23-9) including its classification, application and manufacturing ... top manufacturers of Dutasteride (CAS 164656-23-9) listing their ... etc. , The report further analyzes quantitatively 2009-2014 ...
(Date:7/27/2014)... The European Agricultural Adjuvants Market report ... analysis and forecast of revenue. The agricultural adjuvants market ... million in 2013 to $657.1 million by 2018, at ... Browse through the TOC of the European Agricultural Adjuvants ... analysis provided. It also provides a glimpse of the ...
(Date:7/27/2014)... Bromine market report defines and segments the Bromine market in ... in European region comprises of four major countries. They are ... a dominant share of Bromine market influences the demand for ... the TOC of the Europe Bromine Market report, to get ... TOC of the Europe Bromine Market report. The report provides ...
Breaking Medicine News(10 mins):Health News:Latino Conservation Action Week Launches, Highlights Latinos’ Dedication to Protecting Our Environment 2Health News:Latino Conservation Action Week Launches, Highlights Latinos’ Dedication to Protecting Our Environment 3Health News:Renowned Vancouver Chiropractors Demonstrates Hamstring Release in Vancouver, BC 2Health News:Global and Chinese Dutasteride Industry (CAS 164656-23-9) 2019 Forecasts in New Research Report at ReportsnReports.com 2Health News:Global and Chinese Dutasteride Industry (CAS 164656-23-9) 2019 Forecasts in New Research Report at ReportsnReports.com 3Health News:Global and Chinese Dutasteride Industry (CAS 164656-23-9) 2019 Forecasts in New Research Report at ReportsnReports.com 4Health News:Europe Agricultural Adjuvants Market is Expected to Reach $657.1 million in 2018 - New Report by MicroMarket Monitor 2Health News:Europe Agricultural Adjuvants Market is Expected to Reach $657.1 million in 2018 - New Report by MicroMarket Monitor 3Health News:Europe Agricultural Adjuvants Market is Expected to Reach $657.1 million in 2018 - New Report by MicroMarket Monitor 4Health News:Europe Agricultural Adjuvants Market is Expected to Reach $657.1 million in 2018 - New Report by MicroMarket Monitor 5Health News:Europe Bromine Market is Expected to Reach $111.6 Million in 2018 - New Report by MicroMarket Monitor 2Health News:Europe Bromine Market is Expected to Reach $111.6 Million in 2018 - New Report by MicroMarket Monitor 3Health News:Europe Bromine Market is Expected to Reach $111.6 Million in 2018 - New Report by MicroMarket Monitor 4
... Executive Director, Campaign for,Tobacco-Free Kids, WASHINGTON, Nov. ... the Philip Morris and R.J. Reynolds tobacco companies ... children by defeating a,ballot initiative to increase Oregon,s ... tobacco companies will profit by selling more cigarettes,while ...
... Solutions Announces Opportunity for Patients to Participate in ... Toward Improved Future Dialysis Options -, WARRENDALE, ... provider of advanced sorbent hemodialysis products and services,today ... has begun using,sorbent technology. The study presents the ...
... ALUS ), a worldwide leader in advanced patient ... financial,results on Tuesday, November 13, 2007, following the market ... the results will follow the,same day at 1:30 p.m. ... open to all interested parties live via the conference ...
... Revenue Impact Projected at $7.5 Million in 2008, ... product,manufacturer, Natural Nutrition Inc., (OTC Bulletin Board: NNTN), ... bar manufacturing capabilities by adding state-of-the-art,equipment to produce ... high,demand today. InterACTIVE Nutrition has been manufacturing ...
... Toronto Stock Exchange Symbol: DND, MISSISSAUGA, ON, Nov. 7 ... and operational results for,the three and nine months ended September ... Entered into a licensing and distribution agreement with ... was granted the exclusive right ...
... Laws Expected to Spread Around the Globe, ATLANTA, ... Society,s ambitious goal to cut cancer incidence by,one-fourth by ... in 2004 than they were in 1992. Despite those ... reduction over the first half of the challenge,period was ...
Cached Medicine News:Health News:Tobacco Industry Puts Profits Before Kids in Defeating Oregon Ballot Initiative 2Health News:Home Dialysis Clinical Research Study is Underway - Focuses on At-Home Extended Duration Treatment 2Health News:Home Dialysis Clinical Research Study is Underway - Focuses on At-Home Extended Duration Treatment 3Health News:Alsius Corporation to Host Third Quarter 2007 Financial Results Conference Call/Webcast on November 13, 2007 2Health News:Natural Nutrition Expands Revenue Capabilities with Newly Installed State of the Art Nutrition Bar Line 2Health News:Cipher reports third quarter fiscal 2007 results 2Health News:Cipher reports third quarter fiscal 2007 results 3Health News:Cipher reports third quarter fiscal 2007 results 4Health News:Cipher reports third quarter fiscal 2007 results 5Health News:Cipher reports third quarter fiscal 2007 results 6Health News:Cipher reports third quarter fiscal 2007 results 7Health News:Cipher reports third quarter fiscal 2007 results 8Health News:Cipher reports third quarter fiscal 2007 results 9Health News:Cipher reports third quarter fiscal 2007 results 10Health News:Cipher reports third quarter fiscal 2007 results 11Health News:Cipher reports third quarter fiscal 2007 results 12Health News:Cipher reports third quarter fiscal 2007 results 13Health News:Cipher reports third quarter fiscal 2007 results 14Health News:Cipher reports third quarter fiscal 2007 results 15Health News:Cipher reports third quarter fiscal 2007 results 16Health News:Cipher reports third quarter fiscal 2007 results 17Health News:Cipher reports third quarter fiscal 2007 results 18Health News:Cipher reports third quarter fiscal 2007 results 19Health News:Cipher reports third quarter fiscal 2007 results 20Health News:Cancer Incidence in the United States: A Progress Report 2Health News:Cancer Incidence in the United States: A Progress Report 3
... a combination Spectral Optical Coherence Tomography (OCT) ... provides suberb, high-quality images of the vitreo-retina, ... of spectral technology, OTI's sytem can reach ... per second and provide images with a ...
... The Pulse CDC Compact Cardiac Digital Camera is ... an open, patient-friendly gantry, and provides full sized ... camera into your clinic you need a flexible ... layout. Find out how the Pulse reduces ...
... an ideal gamma camera for ... ability to perform bone and ... perfusion diagnosis and SPECT studies. ... and space efficient solution for ...
... analyzer to perform a Chem 7 panel ... Its test panel -- including sodium, potassium, ... creatinine -- represents the most commonly ordered ... hospital. The addition of hematocrit provides valuable ...
Medicine Products: